Skip to content
2000
Volume 2, Issue 1
  • ISSN: 1574-891X
  • E-ISSN: 2212-4071

Abstract

In the third decade of the Helicobacter pylori era several informations are available on its pathogenetic mechanisms, as well as on therapeutic approaches. A 7-14 day triple or quadruple regimens (proton pump inhibitor together with 2 antibiotics) are currently suggested as first-line treatment, but the success rate following these therapy is constantly decreasing worldwide. Therefore, new drugs are needed to treat such a widespread infection. Several patents of new antibiotics have been claimed in the last 5 years, and some of them showed a very powerful antibacterial activity in vitro, even against clarithromycin and metronidazole resistant strains. Among the new compounds, thienylthiazole derivatives, benzamide derivatives and pyloricidins should be regarded as very promising molecules.

Loading

Article metrics loading...

/content/journals/pri/10.2174/157489107779561706
2007-01-01
2025-11-07
Loading full text...

Full text loading...

/content/journals/pri/10.2174/157489107779561706
Loading

  • Article Type:
    Research Article
Keyword(s): Antibiotics; Helicobacter pylori; therapy
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test